Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
Rangering i aksjer #12088
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Aksjekurs
$2.34
Sist synkronisert: 2026-08-28
Markedsverdi
$621.44M
Endring (1 dag)
-1.06%
Endring (1 år)
55.67%
Land
GB
Handel Autolus Therapeutics plc (AUTL)

Kategori

Aksjeprishistorikk for Autolus Therapeutics plc (AUTL)
Høyeste sluttskurs: $2.28 den 2026-08-01

Laveste sluttskurs: $26.43 den 2018-06-01
Aksjeprishistorikk for Autolus Therapeutics plc fra 2018 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.20 -12.94%
AU
$138.18 473.58%
US
$759.27 7.20%
CH